The company

Founded in 1991, Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the diagnosis of infectious diseases in humans by different techniques – ranging from the traditional cell culture to the most innovating developments in the field of molecular biology. Vircell has been a successful market player worldwide, distributing its products in over 90 countries across the five continents.

The in-house production of all the antigens needed for the development of its kits enables Vircell to work with independence from external suppliers. This peculiarity makes it a flexible company able to guarantee the quality of its products. The reliability of its kits is the result of strict quality controls in accordance with international standards. All distributed tests are validated and CE-marked complying with the European directive 98/79/CE. Vircell is certified ISO 13485, ISO 14001, ISO 9001 AENOR-IQNet and ISO 9001 AENOR and is involved in the process of implementation of GMP standards.


Vircell is a microbial biotechnology company which develops, manufactures and markets ready-to-use kits for the diagnosis of esoteric infectious diseases. Our business culture is based on our people, our high quality products, science, our know-how, and support through R&D.

Since the beginning Vircell has maintained three main objectives:

  1. Produce reagents of the highest quality.
  2. Maintain a clear customer orientation throughout the entire process, from product conception to after-sales service.
  3. Develop innovative products bringing significant advances.


We pursue the goal of becoming the gold standard for the microbiology sector by developing innovate products and techniques for the diagnosis of esoteric infectious diseases.

In order to become an even stronger international player, and to consolidate our global presence, our main goal is to take a step forward, both technically and quantitatively, within a 2-year time frame.



Sign up for our newsletter and you will receive our latest news in your e-mail